Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$1.0T
P/E ratio
55×
Div yield
0.7%
Revenue
$65B
Rev. growth
+45%
Profit margin
28%
Mounjaro sales
$23B
Zepbound sales
$13.5B
In plain English
Eli Lilly is the drugmaker behind tirzepatide — sold as Mounjaro for diabetes and Zepbound for obesity — the GLP-1 blockbuster that has made it the world's most valuable pharma company. It turns living-cell biology and chemistry into medicines, racing to build out factories fast enough to meet demand while plowing the cash into cancer (Verzenio, Loxo), Alzheimer's (Kisunla) and a wave of next-gen drugs like the oral GLP-1 orforglipron.
In simple terms
What Eli Lilly really sells
Eli Lilly is the drugmaker behind tirzepatide — sold as Mounjaro for diabetes and Zepbound for obesity — the GLP-1 blockbuster that has made it the world's most valuable pharma company. It turns living-cell biology and chemistry into medicines, racing to build out factories fast enough to meet demand while plowing the cash into cancer (Verzenio, Loxo), Alzheimer's (Kisunla) and a wave of next-gen drugs like the oral GLP-1 orforglipron.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.